Hormonal
Injectable semaglutide 2.4 mg once weekly produces significant weight loss (mean 15.2% over 104 weeks) and improves cardiometabolic risk factors in adults with obesity.
If you have obesity and struggle to lose weight through diet and exercise alone, ask your doctor about injectable semaglutide (2.4 mg once weekly). It is clinically proven to help you lose an average of 15% of your body weight over two years and improves heart health markers. Be prepared for a slow start to minimize stomach upset, and stick with it as the benefits are significant.
Participants who received semaglutide 2.4 mg over 104 weeks achieved a mean weight loss of 15.2% demonstrating a persistent effect of weight loss and other weight-related endpoints over a 2-year period. STEP trials also showed improvement in cardiometabolic risk factors like reduction in blood pressures, lipids and Hs C-Reactive Protein (CRP) levels.
Why this rating
Based on Phase 3 STEP trials.
Source
ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update (2025)
Sri Venkata Madhu et al. · Indian Journal of Endocrinology and Metabolism · 2025
DOI 10.4103/ijem.ijem_680_25
More from this paper
- South Asian ethnicity is predisposed to 'thin-fat' obesity (normal weight obesity), leading to higher risks of diabetes, hypertension, and dyslipidemia at lower BMIs.Limited
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss (up to 20.9% with 15 mg weekly dose) and is recommended for patients targeting 15-20% weight loss.Weak
- CagriSema (semaglutide + cagrilintide) produces superior weight loss (22.7% at 68 weeks) compared to semaglutide 2.4 mg alone (16.1%) or cagrilintide alone (11.8%).Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →